References
- Takayama, N., Sato, N., O'Brien, S.G., Ikeda, Y. and Okamoto, S. (2002) "Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid", Br. J. Haematol., 119, 106–108.
- Petzer, AL., Gunsilius, E., Hayes, M., Stockhammer, G., Duba, H.C., Schneller, F., et al. (2002) "Low concentrations of STI571 in the cerebrospinal fluid: a case report", Br. J. Haematol., 117, 623 — 625.
- Wolff, N.C., Richardson, JA., Egorin, M. and Ilaria, R.L. Jr. (2003) "The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia", Blood, 101, 5010–5013.
- Chamberlain, M.C. (2002) "A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis", Cancer, 94, 2675–2680.
- Kumagai, T., Morimoto, K., Tsuboi, I., Saitoh, T., Aikawa, S., Kaneita, Y., et al. (1999) "A case of chronic myelogenous leukemia presenting multiple extramedullary tumors localized in cranial dura", Rinsho Ketsueki, 40, 224— 229.
- Nowacici, P., Zdziarska, B., Zyluk, B. and Jankowska-Kurek, I. (1993) "Hemiballismus in patient with blastic phase of chronic myelogenous leukemia", Neuropatol. Pol., 31, 143–148.
- Kantarjian, H.M., Keating, Mi., Talpaz, M., Walters, R.S., Smith, T.L., Cork, A., et al. (1987) "Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients", Am. J. Med., 83, 445 —454.
- Urbano-Ispizua, A., Cervantes, F., Matutes, E., Villamor, N., Pujades, A., Sierra, J., et al. (1993) "Immunophenotypic character-istics of blast crisis of chronic myeloid leukaemia: correlations with clinico-biological features and survival", Leukemia, 7, 1349–1354.
- Padmanabhan, V., Varma, N., Dash, S. and Varma, S. (1996) "Role of immunophenotyping in characterisation of blast crisis of chronic myeloid leukemia— a study of 25 cases", Indian J. Pathol. Micro-biol., 39, 13 — 17.
- Wolff, N.C. and Ilaria, R.L. Jr. (2001) "Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine lcinase inhibitor 5TI571", Blood, 98, 2808–2816.